Nitrogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/245)
-
Patent number: 7618968Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor cells.Type: GrantFiled: August 6, 2007Date of Patent: November 17, 2009Assignee: Cell Therapeutics, Inc.Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A Jenkins, J Peter Klein, Anil M Kumar, John Tulinsky
-
Publication number: 20090275584Abstract: The present invention relates to combinations of imazalil, or a salt thereof, and a biocidal compound which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of imazalil, or a salt thereof, together with one or more biocidal compounds selected from tolylfluanid, dichlofluanid, OIT, DCOIT, terbutryn, chlorothalonil, hexamin and 1,2-benzisothiazolone in respective proportions to provide a synergistic biocidal effect. Compositions comprising these combinations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, engineering material, biodegradable material and textiles against deterioration due to the action of microorganisms such as bacteria, fungi, yeasts, algae, viruses, and the like.Type: ApplicationFiled: May 2, 2007Publication date: November 5, 2009Applicant: JANSSEN PHARMACEUTICA N.V.Inventors: Dany Leopold Jozefien Bylemans, Amber Paula Marcella Thys
-
Publication number: 20090270397Abstract: A method of potentiating the efficacy of an antineoplastic agent such as temozolomide, comprises the administration of an antifolate agent as defined herein. Also disclosed are compositions, including pharmaceutical compositions, comprising the antineoplastic agent and an antifolate agent, and the use of such compounds and compositions thereof to treat a variety of cancers, such as melanoma. Unit dosage forms and kits are also contemplated and disclosed.Type: ApplicationFiled: April 8, 2009Publication date: October 29, 2009Inventors: Seth J. Orlow, Ming Chen
-
Patent number: 7608618Abstract: Compounds of the formula wherein: Y? is O or S, W? is optionally substituted, Z? is selected from the group consisting of wherein Q? is OR7 and R7 is C1-3alkyleneC3-8heterocycloalkyl useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.Type: GrantFiled: April 27, 2005Date of Patent: October 27, 2009Assignee: Icos CorporationInventors: Edward A. Kesicki, John Joseph Gaudino, Adam Wade Cook, Scott Douglas Cowen, Laurence Edward Burgess
-
Patent number: 7608620Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.Type: GrantFiled: November 16, 2006Date of Patent: October 27, 2009Assignee: Cell Therapeutics, Inc.Inventors: Lynn Bonham, Baoqing Gong, Robert E Finney, David M Hollenback, J Peter Klein, David W Leung, Scott A Shaffer, Norina M Tang, John Tulinsky, Thayer H White
-
Publication number: 20090264339Abstract: This invention relates to heterocyclic compounds of the formulas shown in the specification. It also relates to methods for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, and tissue injuries with one of the heterocyclic compounds.Type: ApplicationFiled: November 3, 2008Publication date: October 22, 2009Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Chi-Feng Yen, Cheng-Kung Hu, Chang-Pin Huang, Ying-Huey Huang, Gholam Hossein Hakimelahi, Chi-Hsin Richard King
-
Publication number: 20090258878Abstract: The present invention relates to a Triazine derivative compound, pharmaceutically acceptable salt thereof and a pharmaceutical composition containing them. Compound or composition of the present invention is useful for cancer treatment, and especially has superior effect in breast cancer treatment.Type: ApplicationFiled: July 6, 2007Publication date: October 15, 2009Inventors: Hyun-Kee Kim, Jin-Woo Kim
-
Publication number: 20090252768Abstract: The invention relates to methods of treatment and prevention of aquatic mold infections in aquatic organisms and methods of disinfecting equipment used in raising aquatic organisms. The methods comprise use of one or more stilbene derivatives, including 4,4?-bis-(1,3,5-triazinylamino)stilbene-2,2?-disulfonic acid derivatives.Type: ApplicationFiled: June 27, 2007Publication date: October 8, 2009Inventors: Itzhack Polacheck, Simon Tinman, Rama Falk
-
Publication number: 20090247524Abstract: Compounds represented by formula (1) shown below, pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising such compounds are provided.Type: ApplicationFiled: May 25, 2007Publication date: October 1, 2009Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Takuo Tsukuda, Ken-ichi Kawasaki, Susumu Komiyama, Yoshiaki Isshiki, Yasuhiko Shiratori, Kiyoshi Hasegawa, Takaaki Fukami, Takaaki Miura, Naomi Ono, Toshikazu Yamazaki, Young-Jun Na, Dong-Oh Yoon, Sung-Jin Kim
-
Patent number: 7595343Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: GrantFiled: September 12, 2002Date of Patent: September 29, 2009Assignee: MethylGene, Inc.Inventors: Daniel Delorme, Soon Hyung Woo, Arkadii Vaisburg, Oscar Moradei, Silvana Leit, Stephane Raeppel, Sylvie Frechette, Giliane Bouchain
-
Patent number: 7592451Abstract: The present invention relates to a compound having the formula where Z is an amine, phenoxy, or thiol-containing group, and Y is an alkyl-containing amine. Methods of producing such compounds and using them to treat patients with diabetes and obesity are also disclosed. The present invention also relates to treating such conditions with GADPH inhibitors and screening compounds useful for treating such conditions by using GADPH inhibitors. Compounds can also be screened for their effectiveness in modulating diabetes and obesity with a C. elegans strain.Type: GrantFiled: June 20, 2006Date of Patent: September 22, 2009Assignee: New York UniversityInventors: Young-Tae Chang, Fabio Piano
-
Publication number: 20090233933Abstract: Provided are methods of inhibiting prostaglandin transporter (PGT) activity in mammals. Also provided are methods of determining whether a test compound is an inhibitor of a prostaglandin transporter. Additionally provided are compounds that inhibit prostaglandin transporter activity, and pharmaceutical compositions of those compounds. Methods of inhibiting COX-2 in a mammal are also provided. Additionally, methods of treating pain or inflammation in a mammal are provided.Type: ApplicationFiled: May 15, 2007Publication date: September 17, 2009Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNI, NEW YORK UNIVERSITYInventors: Victor L. Schuster, Yuling Chi, Young-Tae Chang, Jaeki Min
-
Patent number: 7589092Abstract: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.Type: GrantFiled: December 27, 2006Date of Patent: September 15, 2009Assignee: Koronis Pharmaceuticals, IncorporatedInventors: Richard Daifuku, Alexander Gall, Dmitri Sergueev, Dina Sologub, Kevin Harris
-
Publication number: 20090226411Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.Type: ApplicationFiled: December 16, 2008Publication date: September 10, 2009Applicant: AVENTIS PHARMA S.A.Inventors: Patrick MAILLIET, Abdelazize LAOUI, Jean-Francois RIOU, Gilles DOERFLINGER, Jean-Louis MERGNY, Francois HAMY, Thomas CAULFIELD
-
Publication number: 20090227590Abstract: Compounds of formula (I), in salt or zwitterionic form, wherein J, L, M, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.Type: ApplicationFiled: December 22, 2005Publication date: September 10, 2009Inventors: Neil John Press, Stephen Paul Collingwood
-
Publication number: 20090221423Abstract: Pesticidal compositions comprising 3-pyridyl derivatives of formula I wherein the variables and indices are as defined in the description, and an agronomically acceptable carrier, processes for the preparation of compounds I and use of compounds I or II and the compositions comprising them for combating pests.Type: ApplicationFiled: January 19, 2007Publication date: September 3, 2009Applicant: BASF SEInventors: Michael Puhl, Matthias Pohlman, Liliana Parra Rapado, Michael Rack, Thomas Schmidt, Delphine Breuninger, Deborah L. Culbertson, Douglas D. Anspaugh, Henry Van Tuyl Cotter, Hassan Oloumi-Sadeghi, David G. Kuhn
-
Publication number: 20090215777Abstract: The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR3; R1 is a monocyclic or bicyclic carbocyclic or heterocyclic ring of 5 to 10 ring members of which up to two ring members may be heteroatoms selected from N, O and S and the remainder are carbon atoms, the carbocyclic or heterocyclic ring being optionally substituted by one or more substituent groups independently selected from R10; and R2, R3 and R10 are as defined in the claims.Type: ApplicationFiled: May 19, 2006Publication date: August 27, 2009Applicant: Astex Therapeutics Ltd.Inventors: Gianni Chessari, Miles Stuart Congreve, Owen Callaghan, Suzanna Ruth Cowan, Christopher William Murray, Alison Jo-Anne Woolford, Michael Alistair O'Brien, Andrew James Woodhead
-
Publication number: 20090215730Abstract: Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.Type: ApplicationFiled: May 5, 2006Publication date: August 27, 2009Inventors: Rolando Eduardo Rodriguez Fernandez, Roberto Vera Alvarez, Ania De La Nuez Veulens, Yuliet Mazola Reyes, Silvio Ernesto Perea Rodriguez, Boris Ernesto Acevedo Castro, Alexis Musacchio Lasa, Raimundo Ubieta Gomez
-
Patent number: 7579465Abstract: This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals, as well as novel intermediates useful in the preparation of the compounds of formula I.Type: GrantFiled: November 13, 2006Date of Patent: August 25, 2009Assignee: Biota Scientific Managment Pty. Ltd.Inventors: Keith Watson, Guy Krippner, Pauline Stanislawski, Darryl McConnell
-
Publication number: 20090209505Abstract: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.Type: ApplicationFiled: April 7, 2009Publication date: August 20, 2009Applicant: Koronis Pharmaceuticals, IncorporatedInventors: Richard Daifuku, Alexander Gall, Dmitri Sergueev, Dina Sologub, Kevin Harris
-
Publication number: 20090192164Abstract: The invention discloses treating agents of inflammatory bowel disease, which contain p38MAPkinase inhibitor having properties of antedrug as the active ingredient.Type: ApplicationFiled: June 26, 2007Publication date: July 30, 2009Applicant: ASKA Pharmaceutical Co., Ltd.Inventors: Koichi Hasumi, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Jun-ya Kato, Jun Sato, Hiroyuki Suzuki, Hajime Asano, Mami Okada, Yasuhiro Matsumoto, Kazuhiko Shirota
-
Publication number: 20090192134Abstract: A compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof: and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.Type: ApplicationFiled: January 19, 2005Publication date: July 30, 2009Inventors: Premji Meghani, Jeffrey Stonehouse
-
Publication number: 20090192165Abstract: Disclosed are antimicrobial compositions for treating poultry and meat to substantially eliminate bacteria and microorganism harmful to human. The compositions include various combinations of an aliphatic heteroaryl salt, an aliphatic benzylalkyl ammonium salt, a dialiphatic dialkyl ammonium salt, a tetraalkyl ammonium salt and/or trichloromelamine.Type: ApplicationFiled: April 3, 2009Publication date: July 30, 2009Inventors: Steve R. Burwell, Fredrick Busch
-
Patent number: 7566712Abstract: Biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: GrantFiled: July 16, 2004Date of Patent: July 28, 2009Assignee: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Charles A. Blum, Stéphane De Lombaert, Taeyoung Yoon, Xiaozhang Zheng
-
Patent number: 7560450Abstract: The present invention relates to substituted xanthines of general formula the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).Type: GrantFiled: November 18, 2003Date of Patent: July 14, 2009Assignee: Boehringer Ingelheim Pharma GmbH & Co., KGInventors: Matthias Eckhardt, Frank Himmelsbach, Elke Langkopf, Roland Maier, Michael Mark, Mohammad Tadayyon
-
Publication number: 20090163505Abstract: The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.Type: ApplicationFiled: October 23, 2008Publication date: June 25, 2009Inventors: Steven J. COATS, Alexey B. Dyatkin, Wei He, Joseph Lisko, Tamara A. Miskowski, Janet L. Ralbovsky, Mark J. Schulz
-
Publication number: 20090156560Abstract: Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.Type: ApplicationFiled: May 8, 2008Publication date: June 18, 2009Inventors: JOSE LUIS MILLAN, EDUARD SERGIENKO
-
Publication number: 20090143388Abstract: Striatal neurodegenerative disorders, e.g. Parkinson's disease, are treated by administration of an effective dose of an antioxidant compound of formula I, formula II or a pharmaceutically acceptable salt thereof, in a regimen that decreases the adverse effects of the disorder. Such adverse effects can motor deficits, which include catalepsy or akinesia. Also provided are kits and systems for practicing the subject methods, as well as methods of use of agents identified in the screening method of the invention.Type: ApplicationFiled: August 29, 2008Publication date: June 4, 2009Inventors: Kochupurackal Parameswararnnayer Mohanakumar, Goutam Chandra, Reena Haobam, Michael Lionel Selley
-
Publication number: 20090142347Abstract: This invention relates generally to the field of mineralization, and specifically to the role of TNAP in regulating the levels of extracellular inorganic pyrophosphate. The invention provides methods for modulating the activity of TNAP activity; methods for screening for modulators of TNAP activity; modulators of TNAP activity; and methods for treating pathologic conditions known of suspected to be affected by modulation of TNAP activity.Type: ApplicationFiled: September 29, 2005Publication date: June 4, 2009Applicant: THE BURNHAM INSTITUTE FOR MEDICAL RESEARCHInventor: José Luis Millan
-
Patent number: 7534421Abstract: Stable, topically applicable cosmetic/dermatological sunscreen compositions, well suited for the UV-photoprotection of human skin/keratinous materials, contain a thus effective amount of at least one novel s-triazine compound bearing at least one para-aminobenzalmalonic salt substituent.Type: GrantFiled: February 27, 2004Date of Patent: May 19, 2009Assignee: L'OrealInventors: Hervé Richard, Bernadette Luppi
-
Publication number: 20090124576Abstract: Disclosed are triazine derivatives of formula X1 is a bivalent radical of formula A and A? independently from each other are unsubstituted or substituted, straight-chain or branched C1-C12alkylene, which is optionally interrupted by C5-C12cycloalkylene, N, O or S; C5-C12cycloalkylene; biphenylene; C6-C10arylene; or C5-C10arylene-(C1-C12alkylene); R1 is a radical of formula R2 and R3 independently from each other are hydrogen; C1-C12alkyl; OR7; NR7R8; C6-C10aryl; X2 is O, or NH; W1 is C1-C20alkyl; or a group Sp-Sil; Sp is a straight-chain or branched saturated or single or multiple unsaturated C3-C12 hydrocarbon; Sil is a silane; an oligosiloxane; or a polysiloxane moiety; and R4, R5 R6, R7, R8 and R9 independently from each other are hydrogen; C1-C12alkyl; or C3-C12cycloalkyl.Type: ApplicationFiled: May 2, 2007Publication date: May 14, 2009Inventors: Thomas Ehlis, Elek Borsos
-
Publication number: 20090111815Abstract: A carboxamide compound represented by the formula (I): [wherein Q represents a nitrogen-containing 6-membered aromatic heterocyclic group optionally fused with a benzene ring, two or more ring constitutional atoms of the heterocyclic group are a nitrogen atom, and the heterocyclic group may be substituted with at least one group selected from the group consisting of a C1-C3 alkyl group etc.], and a plant disease controlling agent comprising this as an active ingredient.Type: ApplicationFiled: July 12, 2006Publication date: April 30, 2009Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Sadayuki Arimori, Yoshiharu Kinoshita
-
Patent number: 7524874Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, dType: GrantFiled: August 1, 2005Date of Patent: April 28, 2009Assignee: Amgen Inc.Inventors: Elizabeth M. Doherty, Jiawang Zhu, Markian Stec, Mark H. Norman, Vassil I. Ognyanov, Christopher H. Fotsch, Ning Chen, Partha P. Chakrabarti, Liping H. Pettus, Hui-Ling Wang, Xianghong Wang, Premilla Arasasingham
-
Publication number: 20090104145Abstract: Disclosed are mixtures and compositions for controlling invertebrate pests relating to combinations comprising (a) 3-bromo-N-[4-cyano-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide, an N-oxide, or a salt thereof, Formula (1) and (b) at least one invertebrate pest control agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones, GABA-regulated chloride channel blockers, juvenile hormone mimics, ryanodine receptor ligands, octopamine receptor ligands, mitochondrial electron transport inhibitors, nereistoxin analogs, pyridalyl, flonicamid, pymetrozine, dieldrin, metaflumizone, biological agents, and salts of the foregoing. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a mixture or composition of the invention.Type: ApplicationFiled: July 22, 2005Publication date: April 23, 2009Inventors: Kenneth Andrew Hughes, George Philip Lahm, Thomas Paul Selby, Thomas Martin Stevenson, Isaac Billy Annan
-
Publication number: 20090093481Abstract: (1,3,5)-Triazinyl phenyl hydrazones are effective at controlling insects.Type: ApplicationFiled: September 26, 2008Publication date: April 9, 2009Applicant: Dow AgroSciences LLCInventors: Noormohamed M. Niyaz, Katherine A. Guenthenspberger, Ricky Hunter, Annette V. Brown, Jaime S. Nugent
-
Publication number: 20090093485Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).Type: ApplicationFiled: October 26, 2005Publication date: April 9, 2009Applicant: ASTRAZENECA ABInventors: Hakan Bladh, Krister Henriksson, Vijaykumar Hulikal, Matti Lepisto
-
Publication number: 20090093443Abstract: The present invention relates to combinations of 4-bromo-2-(4-chloro-phenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, and a biocidal compound which provide an improved protecting effect against fouling organisms.Type: ApplicationFiled: April 10, 2007Publication date: April 9, 2009Applicant: JASSEN PHARMACEUTICA N.V.Inventors: Tony Mathilde Jozef Kempen, Ludo Antoinnette De Witte, Jan Pieter Hendrik Bosselaers
-
Publication number: 20090093487Abstract: A composition comprising at least one physiologically tolerated film-forming agent, at least one physiologically tolerated solvent, at least one plasticizer and a compound of the formula I or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing. The composition is suitable for treatment of androgenic alopecia or hirsutism, that is, for avoiding undesirable hair growth, and for treatment of seborrhea and acne, and can furthermore be employed in cosmetics.Type: ApplicationFiled: November 20, 2008Publication date: April 9, 2009Inventors: Karl Theodor Kraemer, Manfred Bohn
-
Publication number: 20090093486Abstract: N-Azinyl-N?-aryl ureas and thioureas derivatives are effective at controlling insects.Type: ApplicationFiled: September 26, 2008Publication date: April 9, 2009Applicant: Dow AgroSciences LLCInventors: Noormahamed M. Niyaz, Ricky Hunter, Timothy C. Johnson, Tony K. Trullinger, Annette V. Brown, Kristy Bryan
-
Patent number: 7514442Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.Type: GrantFiled: March 31, 2006Date of Patent: April 7, 2009Assignees: Schering Corporation, Pharmacopeia, Inc.Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Ronald J. Doll, Viyyoor M. Girijavallabhan, Carmen S. Alvarez, Tin Yau Chan, Chad Knutson, Vincent Madison, Thierry O. Fischmann, Lawrence W. Dillard, Vinh D. Tran, Zhen Min He, Ray Anthony James, Haengsoon Park
-
Publication number: 20090082355Abstract: A method of combating root weevils comprising contacting the root weevils or their food supply, habitat, breeding grounds or their locus with a pesticidally effective amount of a compound of the formula (I) wherein W is Cl or CF3; X and Y are each independently Cl or Br; R1 is alkyl, alkenyl, alkynyl, or cycloalkyl optionally substituted with 1 to 3 halogens, or alkyl which is substituted by alkoxy; R2 and R3 are alkyl or may be taken together to form cycloalkyl optionally substituted by 1 to 3 halogens; R4 is H or C1-C6-alkyl, or the enantiomers or salts thereof.Type: ApplicationFiled: December 21, 2006Publication date: March 26, 2009Applicant: BASF SEInventors: Wolfgang von Deyn, Samuel Wells, Hassan Oloumi-Sadeghi, Nigel Armes, David G. Kuhn
-
Patent number: 7507734Abstract: Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, R1 and R2 are detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).Type: GrantFiled: November 16, 2006Date of Patent: March 24, 2009Assignee: Aventis Pharma S.A.Inventors: Swen Hoelder, Gunter Muller, Karl Schoenafinger, David William Will, Hans Matter, Martin Bossart, Cecile Combeau, Christine Delaisi, Ingrid Sassoon, Anke Steinmetz, Didier Benard
-
Publication number: 20090074887Abstract: There are described new active compound combinations of a compound of the formula (I) with known fungicidal active compounds, and their use for the control of phytopathogenic fungi.Type: ApplicationFiled: May 9, 2008Publication date: March 19, 2009Applicant: Bayer CropScience AGInventors: Wilhelm Brandes, Heinz-Wilhelm Dehne, Stefan Dutzmann, Karl-Heinz Kuck, Bernd-Wieland Kruger
-
Publication number: 20090074825Abstract: The present invention includes methods, articles, compositions and colorant dyes and pigments that include biocidal N-halamine dye composition having two or more heterocyclic ring structures attached to one or more N-halamine groups, wherein one or more halogens associate with the one or more one or more N-halamine groups to affect biocidal activity.Type: ApplicationFiled: September 19, 2008Publication date: March 19, 2009Applicant: Board of Regents, The University of Texas SystemInventors: Yuyu Sun, Jie Luo
-
Publication number: 20090075867Abstract: Compounds useful in the treatment of metastatic melanoma and other cancers containing a triazine ring scaffold are described. These compounds may be classified into two groups: (1) two disubstituted triazine rings are covalently linked by an organic linker to each other and (2) one trisubstituted triazine ring.Type: ApplicationFiled: May 19, 2006Publication date: March 19, 2009Inventors: Lyne Gagnon, Boulos Zacharie, Christopher Penney
-
Publication number: 20090069305Abstract: The present invention relates to substituted nitrogen-containing heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using any of these derivatives and compositions for H4 receptor activity modulation and the treatment of states mediated by histamine H4 receptor activity.Type: ApplicationFiled: September 11, 2008Publication date: March 12, 2009Inventors: Michael D. Gaul, Bao-Ping Zhao, Xizhen Zhu
-
Publication number: 20090068169Abstract: The present invention describes new compounds which are useful for binding to the tail or Fc portion of immunoglobulins and so have utility in those applications which require the non-covalent binding interaction of a molecule with the Fc portion of immunoglobulins. Such applications include the detection and purification of immunoglobulins as well as the treatment of certain autoimmune diseases.Type: ApplicationFiled: September 2, 2005Publication date: March 12, 2009Inventors: Christopher Penney, Boulos Zacharie, Shaun D. Abbott, Jean-Francois Bienvenu, Alan D. Cameron, Jean-Simon Duceppe, Abdallah Ezzitouni, Daniel Fortin, Karine Houde, Nancie Moreau, Nicole Wilb, Brigitte Grouix, Lyne Gagnon
-
Patent number: 7501511Abstract: The present invention is directed towards a process for resolving a racemic amino compound derived from dihydro-1,3,5-triazines. The invention is also directed towards the enantiomers of amino derivatives of dihydro-1,3,5-triazines and to their use for the preparation of medicaments, in particular for the treatment of diabetes and malaria.Type: GrantFiled: April 6, 2004Date of Patent: March 10, 2009Assignee: Merck Patent GmbHInventors: GĂ©rard Moinet, Daniel Cravo, Thierry Passemar
-
Publication number: 20090062236Abstract: The compositions and methods disclosed herein provide heterobifunctional programmable genotoxic compounds that can be designed to kill selected cells present in a heterogenous cell population. The present compounds comprise a first agent that inflicts damage on cellular DNA, and a second agent that attracts a macromolecular cell component such as a protein, which in turn shields genomic lesions from repair. Unrepaired lesions therefore persist in the cellular genome and contribute to the death of selected cells. In contrast, lesions formed in nonselected cells, which lack the cell component, are unshielded and thus are repaired. As a result, compounds described herein are less toxic to nonselected cells. Compounds of this invention can be designed to cause the selective killing of transformed cells, viral-infected cells and the like.Type: ApplicationFiled: January 29, 2007Publication date: March 5, 2009Applicant: Massachusetts Institute of TechnologyInventors: John M. Essigmann, Robert G. Croy, Kevin J. Yarema, Marshall Morningstar
-
Publication number: 20090054308Abstract: Methods of treating pulmonary hypertension are disclosed. Particular methods comprise the administration of a tryptophan hydroxylase inhibitor and at least one other active pharmaceutical ingredient to patient in need thereof. Pharmaceutical formulations are also disclosed.Type: ApplicationFiled: July 9, 2008Publication date: February 26, 2009Inventor: Arthur T. Sands